The Australia Ablation Technology Market was valued at $1794.7 Million in 2026 and projected to reach to $3017.6 Million by 2031, representing a compound annual growth rate of 11.0%. Australia's ablation technology market demonstrates strong growth momentum, driven by increasing adoption of minimally invasive procedures and advancing healthcare infrastructure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Australia's ablation technology market is valued at USD 1,794.7 million in 2026, with a robust 11% CAGR projected through 2031, reaching USD 3,017.6 million. This growth aligns with the global expansion rate of 11.2%, positioning Australia as a key market in the Asia-Pacific region.
Cryoablation technology leads the Australian market, leveraging extreme cold therapy for minimally invasive treatments. Strong adoption across oncology, cardiology, and dermatology applications reflects growing clinician confidence and patient preference for less invasive surgical alternatives in Australian healthcare settings.
Australia's advanced healthcare system, high Medicare penetration, and strong private hospital networks support rapid adoption of cutting-edge ablation technologies. Government funding initiatives and private insurance coverage drive accessibility and market expansion across metropolitan and regional centers.
Increasing prevalence of cardiac arrhythmias, skin cancers, and solid tumors in Australia creates sustained demand for ablation procedures. Growing awareness among Australian physicians and patients about minimally invasive treatment benefits continues to expand the addressable patient population.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | ASIA PACIFIC (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 11.2% from 2026 to 2031 |
| Largest Segment | RADIOFREQUENCY ABLATION (Type) |
| Market Size Base Year (Billions) | ~USD 16.21 (2026) |
| Revenue Forecast (Billions) | ~USD 27.56 (2031) |
| Segments Covered | Type, Technology, Product, Application, End User |
5 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| JOHNSON & JOHNSON | United States | Public Company | Oncology and Immunology (Innovative Medicine),Neuroscience, Cardiovascular & Metabolism, Infectious Diseases,Surgery and Interventional (MedTech), |
| MEDTRONIC | Ireland | Public Company | Cardiovascular Portfolio,Neuroscience Portfolio,Medical Surgical Portfolio (incl. Diabetes), |
| BOSTON SCIENTIFIC CORPORATION | United States | Public Company | Cardiovascular (Interventional Cardiology, Structural Heart, CRM, Peripheral),MedSurg – Endoscopy (GI, Pancreaticobiliary, Infection Prevention),MedSurg – Urology and Pelvic Health, |
| ABBOTT LABORATORIES | United States | Public Company | Medical Devices,Diagnostic Products,Nutritional Products, |
| ATRICURE, INC. | United States | Public Company | Surgical RF ablation systems (Isolator Synergy, pens, linear devices),Cryoablation and nerve block (cryoICE, cryoSPHERE, cryoXT),LAA exclusion and soft-tissue closure (AtriClip, LARIAT), |
| ANGIODYNAMICS | United States | Public Company | Peripheral vascular and thrombus management (Auryon, AlphaVac, AngioVac, thrombolytic catheters),Interventional oncology and ablation (NanoKnife, Solero, related disposables),Vascular access, drainage, and ports (catheters, ports, microintroducer kits), |
| CONMED CORPORATION | United States | Public Company | Orthopedic and sports medicine (implants, Hall power tools, arthroscopy systems),General surgery (AirSeal, Buffalo Filter, endomechanical, electrosurgical systems),Endoscopic technologies (GI therapeutic and diagnostic devices), |
| OLYMPUS CORPORATION | Japan | Public Company | Gastrointestinal Solutions (endoscopes, devices, services),Urology (visualization, stone management, BPH, bladder cancer),Respiratory (bronchoscopy, lung cancer, COPD), |
| VARIAN MEDICAL SYSTEMS, INC. | United States | Private Company | Oncology Systems – Treatment Delivery Hardware (Linacs, Brachytherapy Afterloaders, Accessories),Oncology Systems – Software (Planning, Information Management, QA, AI-based Adaptive),Proton Solutions, |
| SMITH+NEPHEW | United Kingdom | Public Company | Orthopaedics (Knee, Hip, Trauma & Extremities, Other Reconstruction),Sports Medicine & ENT (Joint Repair, Arthroscopic Enabling Technologies, ENT Solutions),Advanced Wound Management – Advanced Wound Care, |
| STRYKER | United States | Public Company | MedSurg and Neurotechnology,Orthopaedics Implants and Robotics, |
| MICROPORT SCIENTIFIC CORPORATION | China | Public Company | Cardiovascular Devices (coronary stents, balloons, accessories),Orthopedics Devices (reconstructive joints, spine, trauma),Cardiac Rhythm Management, |
| MERIT MEDICAL SYSTEMS | United States | Public Company | Cardiovascular – access, hemostasis, fluid management, hemodynamic monitoring,Peripheral intervention – angiography, drainage, delivery systems, embolotherapy,Oncology and spine – soft tissue biopsy, vertebral augmentation, RF ablation, |
Johnson & Johnson is a publicly traded American healthcare conglomerate founded in 1886 with 138,200 employees.
Medtronic is a publicly traded medical device company headquartered in Ireland, founded in 1949 with 95,000 employees.
Boston Scientific Corporation is a publicly traded U.S. medical device manufacturer founded in 1979 with 59,000 employees.
Abbott Laboratories is a publicly traded American healthcare company founded in 1888 with 115,000 employees.
AtriCure, Inc. is a publicly traded U.S. medical device company founded in 2000 with 1,350 employees.
AngioDynamics is a publicly traded U.S. medical device company founded in 1988 with 632 employees.
CONMED Corporation is a publicly traded U.S. medical device and equipment manufacturer founded in 1970 with 3,900 employees.
Olympus Corporation is a publicly traded Japanese manufacturer founded in 1919 with 28,138 employees.
Varian Medical Systems, Inc. is a privately held U.S. company founded in 1948 with 10,000 employees.
Smith+Nephew is a publicly traded British medical device and healthcare company founded in 1856 with 16,988 employees.
Stryker is a publicly traded U.S. medical device and surgical equipment company founded in 1941 with 56,000 employees.
MicroPort Scientific Corporation is a publicly traded Chinese medical device manufacturer founded in 1998 with 6,547 employees.
Merit Medical Systems is a publicly traded U.S. medical device company founded in 1987 with 7,500 employees.
Cryoablation is forecast to reach $3,017.6 million by 2031, growing from $1,794.7 million in 2026 at an 11.0% CAGR.
Cryoablation is utilized across oncology for tumor destruction, cardiology for arrhythmia treatment, and dermatology for skin lesion removal.
Cryoablation growth is driven by minimally invasive benefits, shorter recovery times, improved imaging guidance, and expanding reimbursement policies.
Cryoablation offers precise tissue destruction with reduced collateral damage and faster patient recovery compared to radiofrequency and microwave ablation.
Cryoablation adoption is accelerating in North America and Europe due to advanced healthcare infrastructure, with emerging markets showing increasing uptake.
This study involved four major activities in estimating the current ablation technology market size. First, extensive secondary research was conducted to gather information on the market, including related and parent markets. The next step involved validating these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the ablation technology market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the ablation technology market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.
A breakdown of the primary respondents for the ablation technology market is provided below:

Note: Companies are classified into tiers based on their total revenue. Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion. C-level primaries include CEOs, CFOs, COOs, and VPs. Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Source: MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the ablation technology market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players. Also, the ablation technology market was split into various segments and subsegments based on:
The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

After arriving at the overall size of the ablation technology market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.
Ablation is the removal of unwanted growth of tissue by using extreme heat, cold, or lasers. The ablation products are utilized to treat a wide range of conditions, including various kinds of cancer such as lung, breast, kidney, prostate, orthopedic treatment, cosmetic surgery, pain management, gynecological treatment, urological treatment, ophthalmological treatment, and others. The primary end users of this market are hospitals and surgical centers, ablation centers, ambulatory surgery centers, medical spas, and aesthetic & dermatology clinics.
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Full forecast, segment splits, and company analysis for all Ablation Technology Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report